Kailera Therapeutics, Inc. Common Stock (KLRA) Stock Price
KLRAStock
$16.21
Market Cap$2.10B
P/E—
PEG Ratio—
Div yield—
Beta2.14
KLRA Share Price Chart
Favorite Metrics
Price vs S&P 500 (4W)-7.95%
VGM Score26.67
KLRA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.76 | -$1.09 | -43.42%(-$0.33) | |
| Q1 2026 | -$0.55 | -$3.65 | -565.09%(-$3.10) |
KLRA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
4.22
4.30
4.33
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KLRAKailera Therapeutics, Inc. Common Stock | — | — | D | $16.21 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Kailera Therapeutics, Inc. Common Stock
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.